UC
Oncology · 2011–2024
12decisions
6medicines
8carried consumer input
23individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab adjuvant treatment for high-risk muscle invasive urothelial carcinoma (MIUC) in patients who have received prior neoadjuvant platinum-based chemotherapy, or… | Mar 2024 | Recommended with restriction | input received |
| enfortumab vedotin First-line treatment of locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer in patients who have not previously received systemic therapy… | Nov 2024 | Recommended with restriction | 11 individuals BEAT Bladder Cancer Australia · Rare Cancers Australia |
| nivolumab First-line treatment of cisplatin-eligible adult patients with unresectable or metastatic urothelial carcinoma (u/mUC) in combination with… | Nov 2024 | Recommended with restriction | input received Rare Cancers Australia · BEAT Bladder Cancer Australia |
| enfortumab vedotin Treatment of adult patients with locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer who have progressed on or after platinum-containing… | Feb 2023 | Recommended with restriction | 1 individuals |
| avelumab Maintenance treatment of locally advanced (Stage III) or metastatic (Stage IV) urothelial carcinoma in patients whose disease has not progressed following… | Mar 2022 | Recommended with restriction | no section in document |
| enfortumab vedotin Treatment of patients with locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer who have progressed on or after platinum-containing… | Mar 2022 | Not recommended | 1 individuals Rare Cancers Australia · BEAT Bladder Cancer Australia · Medical Oncology Group |
| avelumab Maintenance treatment of locally advanced (Stage III) or metastatic (Stage IV) urothelial carcinoma in patients whose disease has not progressed following… | Mar 2021 | Recommended with restriction | input received BEAT Bladder Cancer Australia · Rare Cancers Australia · Medical Oncology Group · Eastern Cooperative Oncology Group |
| durvalumab Treatment of patients with locally advanced or metastatic urothelial cancer who have disease progression during or following platinum-based chemotherapy. | Jul 2019 | Not recommended | 1 individuals |
| vinflunine Treatment of adult patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract (TCCU) after failure of a prior… | Jul 2017 | Not recommended | none received |
| pembrolizumab Treatment of patients with locally advanced or metastatic urothelial cancer after failure of a platinum-containing regimen. | Nov 2017 | Not recommended | 9 individuals Rare Cancer Australia |
| vinflunine Treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing… | Nov 2015 | Not recommended | none received |
| vinflunine Treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing… | Nov 2011 | Not recommended | no section in document |
Who spoke
BEAT Bladder Cancer Australia · Rare Cancers Australia · Medical Oncology Group · Eastern Cooperative Oncology Group · Rare Cancer Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 8 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.